Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.5600 (-6.29%) ($6.5600 - $6.5600) on Tue. Feb. 23, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.85% (three month average) | RSI | 42 | Latest Price | $6.5600(-6.29%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -2.4% a day on average for past five trading days. | Weekly Trend | AUTL declines -6.6% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) LIT(13%) SKYY(13%) BNDX(12%) XBI(12%) ICLN(11%) | Factors Impacting AUTL price | AUTL will decline at least -2.425% in a week (0% probabilities). USO(-8%) TBT(-8%) UNG(-6%) VIXM(-3%) SHY(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.425% (StdDev 4.85%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.9(-205.18%) | Resistance Level | $7.53 | 5 Day Moving Average | $7.02(-6.55%) | 10 Day Moving Average | $7.13(-7.99%) | 20 Day Moving Average | $7.53(-12.88%) | To recent high | -44.8% | To recent low | 0% | Market Cap | $343m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |